OTCMKTS:AXIM AXIM Biotechnologies (AXIM) Stock Price, News & Analysis → Nvidia’s Quiet $1 Trillion Pivot (From Weiss Ratings) (Ad) Free AXIM Stock Alerts $0.0068 0.00 (0.00%) (As of 06/11/2024 ET) Add Compare Share Share Today's Range$0.0065▼$0.007650-Day Range$0.0068▼$0.015652-Week Range$0.01▼$0.04Volume393,522 shsAverage Volume428,105 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get AXIM Biotechnologies alerts: Email Address Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About AXIM Biotechnologies Stock (OTCMKTS:AXIM)AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases. The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests. It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.Read More AXIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXIM Stock News HeadlinesMay 29, 2024 | finance.yahoo.comAXIM Biotechnologies Receives Medical Device Manufacturing LicenseMay 25, 2024 | finance.yahoo.comAXIM Biotechnologies, Inc. (AXIM)May 24, 2024 | msn.comQueenmother of Upper Axim recognised for contributions towards educationMay 11, 2024 | morningstar.comAXIM Biotechnologies Inc AXIMApril 18, 2024 | seekingalpha.comADPT Adaptive Biotechnologies CorporationApril 4, 2024 | msn.comAxim youth appeal for sports infrastructureMarch 27, 2024 | globenewswire.comVIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024March 7, 2024 | msn.comWe Want Peaceful Elections – Axim YouthFebruary 20, 2024 | finance.yahoo.comAXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical ValidationFebruary 20, 2024 | globenewswire.comAXIM® Biotechnologies' Tear Based Testing Platform Continues to Gain Traction After Successful Clinical ValidationFebruary 7, 2024 | msn.comAxim Fishermen Hail GovtFebruary 6, 2024 | msn.comMASLOC Trial: Daniel Axim Denies ChargesDecember 21, 2023 | msn.comAXIM and Auer partner for dry eye disease assay productionDecember 20, 2023 | finance.yahoo.comAXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay ProductionDecember 11, 2023 | msn.comTullow builds 14-unit dormitory block for Axim Girls SHSDecember 2, 2023 | seekingalpha.comLLBO Lifeline Biotechnologies, Inc.December 2, 2023 | seekingalpha.comCollPlant Biotechnologies Ltd. (CLGN) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | msn.comCourt Orders Mental Test For Axim In MASLOC TrialNovember 1, 2023 | msn.comAxim Fishermen Plead For More PremixSeptember 12, 2023 | stockhouse.comAXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson's DiseaseSeptember 12, 2023 | finance.yahoo.comAXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s DiseaseSeptember 10, 2023 | finance.yahoo.comAXIM - AXIM Biotechnologies, Inc.August 1, 2023 | finance.yahoo.comAXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody TestJuly 12, 2023 | finance.yahoo.comUpdate: AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers NationwideJuly 12, 2023 | finance.yahoo.comUpdate: AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers NationwideSee More Headlines Receive AXIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AXIM Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:AXIM CUSIPN/A CIK1514946 Webaximbiotech.com Phone(858) 923-4422FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. John W. Huemoeller II (Age 69)President, CEO & Director Comp: $420kMr. Robert T. Malasek (Age 56)CFO & Secretary Comp: $90kMs. Catalina Valencia J.D. (Age 75)Co-Founder & CEO of Sapphire Biotech, Inc. Comp: $187.5kMr. Kurt Phinney (Age 51)Chief Operating Officer Dr. Sergei A. Svarovsky M.B.A.Ph.D., Chief Scientific Officer & Co-Founder of Sapphire Biotech, Inc.Dr. Douglas Lake Ph.D.Chief Clinical Officer of Sapphire Biotech, Inc.Dr. Alim Seit-Nebi Ph.D.CTO & Co-Founder of Sapphire Biotech, Inc.Mr. Jeffrey A. BusbySenior Vice President of Business DevelopmentDr. Joseph Tauber M.D. (Age 67)Chief Medical Officer & Chairman of the Medical Advisory Board Dr. Maria J. Gonzalez Moa Ph.D.Vice President of Product Development - Sapphire Biotech, Inc.More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors AXIM Stock Analysis - Frequently Asked Questions How have AXIM shares performed in 2024? AXIM Biotechnologies' stock was trading at $0.0190 at the start of the year. Since then, AXIM shares have decreased by 64.1% and is now trading at $0.0068. View the best growth stocks for 2024 here. Are investors shorting AXIM Biotechnologies? AXIM Biotechnologies saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 12,600 shares, a decline of 92.0% from the April 30th total of 157,000 shares. Based on an average daily volume of 741,400 shares, the days-to-cover ratio is currently 0.0 days. View AXIM Biotechnologies' Short Interest. What other stocks do shareholders of AXIM Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other AXIM Biotechnologies investors own include Cronos Group (CRON), Tilray (TLRY), KushCo (KSHB), Curaleaf (CURLF), Charlotte's Web (CWBHF), Fulcrum Therapeutics (FULC) and Alibaba Group (BABA). How do I buy shares of AXIM Biotechnologies? Shares of AXIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:AXIM) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AXIM Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AXIM Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.